source
- Zymeworks CEO says $1 billion Theravance acquisition offers strong value despite recent setbacksZymeworks chief executive Kenneth Galbraith explained why the company believes its near-$1 billion purchase of Theravance makes strategic sense. He noted that Theravance has faced operational diff…
- 5 takeaways from STAT’s investigation into microhospital operator Nutex HealthRead the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.